

Daftar Pustaka

- Abdel-Qadir, H., Roifman, I., Wijeysondera, H.C., 2015. Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome. *CMAJ* 3(4): 438-446.
- Afdhal, A.F., 2011. *Farmakoekonomi: Pisau analisis terbaru dunia farmasi* (pp. 22-24). Jakarta: Samira Media Utama.
- Andrikopoulos, G., Terentes-Printzios, D., Tzeis, S., Vlachopoulos, C., Varounis, C., Nikas, N., *et al.*, 2016. Epidemiological characteristics, management and early outcomes of acute coronary syndromes in Greece: The PHAETHON study. *Hellenic J. Cardiol.* 57(3): 157-166.
- Aurellia, A., dan Pujiyanti, E., 2015. Biaya satuan dan pemulihan biaya (cost recovery rate) layanan pasien acute coronary syndrome dengan rawat inap di rumah sakit x tahun 2015. *J. Eko. Kes. Indo.* 1: 132-137.
- Arnold, R.J.G., 2010. *Pharmacoeconomics: From Theory to Practice*, Advances in Colloid and Interface Science: 13. United States: New York.
- Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI, 2013. Riset Kesehatan Dasar (RISKESDAS) 2013. *Lap. Nas.* 2013: 1-384.
- Becker, R.C., Bassand, J.P., Budaj, A., Wojdyla, D.M., James, S.K., Cornel, J.H., *et al.*, 2011. bleeding complications with the p2y₁₂ receptor antagonists clopidogrel and ticagrelor in the platelet inhibition and patient outcomes (PLATO) Trial. *Europ. Heart J.* 32: 2933-2944.
- Birkett, D.J., 2002. WHO Drug Information. World Health Organization.
- Boisclair, D., Décarie, Y., Laliberté-Auger, F., Michaud, P.C., Vincent, C., 2018. The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada. *PLoS One* 13: 1-13.
- Burgess, S., Mallard, T.A., Juergens, C.P., 2012. Review of ticagrelor in the management of acute coronary syndromes. *Expert Opin. Drug Metab. Toxicol* 8(10): 1315-1325.
- Butler, K., and Teng, R., 2012. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. *J. Clin. Pharmacol.* 52: 1388-1398.
- Cambria-Kelly, J.A., Gandhi, P.J., 2002. Possible mechanisms of aspirin resistance. *J. Thromb. Thrombolysis* 13(1): 49-56.

- Carey, M.G., 2016. Acute coronary syndrome and st segment monitoring. *Crit. Care Nurs. Clin. North Am.* 28: 347–355.
- Chan, M.Y., Du, X., Eccleston, D., Ma, C., Mohanan, P.P., Ogita, M., Shyu, K.G., Yan, B.P., Jeong, Y.H., 2016. Acute coronary syndrome in the Asia-Pacific region. *Int. J. Cardiol.* 202: 861-869.
- Chin, C.T., Mellstrom, C., Chua, T.S.J., Matchtar, D.B., 2013. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. *Singapore Med. J.* 54(3): 169-175.
- Cordero, A., Moreno-Arribas, J., Bertomeu-Gonzales, V., Agudo, P., Miralles, B., Masia, M.D., Lopez-Palop, R., Bortomeu-Martinez, V., 2012. Low levels of high-density lipoproteins cholesterol are independently associated with acute coronary heart disease in patients hospitalized for chest pain. *Rev. Esp. Cardiol.* 65(4): 319-325.
- Cowper, P.A., Pan, W., Anstrom, K.J., Kaul, P., Wallentin, L., Davidson-Ray, L., et al., 2015. Economic analysis of ticagrelor therapy from a U.S. Perspective. *JACC.* 65(5): 465-476.
- Daghistani, T.A., Elshawi, R., Sakr, S., Ahmed, A.M., Al-Thwayee, A., Al-Mallah, M.H., 2019. Predictors of in-hospital length of stay among cardiac patients: A machine learning approach. *Int. J. Cardiol.* 288: 140-147.
- Departemen Kesehatan RI. 2007. *Pharmaceutical care* untuk pasien penyakit jantung koroner: Fokus Sindrom Koroner Akut. Indonesia: Jakarta.
- Dipiro, J.T., Talbert, R L., Yee g c., Matzke, G.R., Wells, B.G., Posey, L.M., 2011. *Pharmacotherapy: a pathophysiologic approach*, 8th ed., MC Graw-Hill, United State of America.
- Earle, N.J., Poppe, K.K., Doughty, R.N., Rolleston, A., Kerr, A.J., Legget, M.E., 2018. Clinical characteristics and burden of risk factors among patients with early onset acute coronary syndromes: The ANZACS-QI New Zealand National cohort (ANZACS-QI 17). *Hear. Lung Circ.* 27: 568-575.
- Gaglia, M.A., Clavijo, L., 2013. Cardiovascular pharmacology core reviews: aspirin. *J. Cardiovasc. Pharmacol. Ther.* 18: 505-513.
- Garcia, M.M., Ortega, M.S., Arriaga, I.V., Lemus, E.H., Herrera, R.G., and Vallejo M., 2018. A systematic approach to analyze the social determinants of cardiovascular disease. *PloS. ONE* 13(1): 1-25.

- Gasche, D., Ulle, T., Meier, B., Greiner., Roger-Alex., 2103. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. *J. Med. Scien.* 43: 1-9.
- Goto, S., Huang, C-H., Park, S-J., Emanuelsson, H., Kimura, T., 2015. Ticagrelor vs. clopidogrel in japanese, korean and taiwanese patients with acute coronary syndrome. *Circ. J.* 79: 2452-2460.
- Harun, S., Alwi, I. 2009. Infark Miokard Akut Tanpa Elevasi ST,dalam Sudoyo, A.W., Setyohadi, B., Alwi, I., Simadibrata, M. dan Setiati, S., *Buku ajar ilmu penyakit dalam*, edisi v. Jakarta, InternaPublishing: 1757-1763.
- Hankey, G.J., Eikelboom, J.W., 2003. Antiplatelet drugs. *Med. J. Aust.* 178: 568-574.
- Hedayati, T., Yadav, N., Khanagavi, J., 2018. Non–ST-Segment Acute Coronary Syndromes. *Cardiol. Clin.* 36: 37-52.
- Hermanides, R.S., Kilic, S., J van't Hof, A.W., 2018. Optimal pharmacological therapy in st-elevation myocardial infarction. *Neth. Heart J.* 26: 296-310.
- Ho, P.M., Bryson, C.L., Rumsfeld, J.S., 2009. Medication adherence: Its importance in cardiovascular outcomes. *Circ. J.* 119(23): 3028-3035.
- Hussain, M.A., Al Mamun, A., Peters, S.A., Woodward, M., Huxley, R.R., 2016. The burden of cardiovascular disease attributable to major modifiable risk factors in indonesia. *J. Epidemiol.* 26: 515-521.
- Iskandar, Hadi, A., Alfridsyah, 2017. Faktor risiko terjadinya penyakit jantung koroner pada pasien RSU Meuraxa Banda Aceh. *Aceh Nutr. J.* 2: 32-42.
- Jiang, M., You, J.H.S., 2017. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. *Clin. Cardiol.* 40: 789-796.
- Kandou, R.D., Tumade, B., Jim, E.L., Joseph, V.F.F., Manado, S.R., Kardiologi, B., Kedokteran, F., Sam, U., Manado, R., 2016. Prevalensi sindrom koroner akut di RSUP Prof. Dr. R. D. Kandou Manado periode 1 Januari 2014 – 31 Desember 2014. *J. e-Clinic.* 4: 223-230.
- Kaplan, R., Heckbert, S., Furberg, C., Psaty, B., 2002. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. *J. Clin. Epidemiol.* 55: 654–664.
- Kemenkes RI, 2013. Pedoman penerapan kajian farmakoekonomi. Jakarta: Kemenkes RI.

- Kemenkes RI, 2017. Penyakit jantung penyebab kematian tertinggi, kemenkes ingatkan CERDIK. *Kemen. Kes. RI*. 2015-2016.
- Leander, K., Wiman, B., Hallqvist, J., Anderson, T., Ahlbom, A., de Faire, U., 2007. Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP). *Eur. J. Cardiovasc. Prev. Rehabil.* 14(4): 532-537.
- Levine, G.N., Bates, E.R., Bittl, J.A., Brindis, R.G., Fihn, S.D., Fleisher, L.A., *et al.* 2016. ACC/AHA guideline focused update on duration of dual anti-platelet therapy in patients with coronary artery disease: a report of the American college of cardiology/ American heart association task force on clinical practice guidelines. *JACC.*: 1-57.
- Lin, S.L., Chang, H.M., Liu, C.P., Chou, L.P., Chan, J.W., 2011. Clinical evidence of interaction between clopidogrel and proton pump inhibitors. *J. World Cardiol.* 3(5): 153-164.
- Ma, X., Ma, C., Yun, Y., Zhang, Q., Zheng, X., 2014. Safety and efficacy outcomes of preoperative aspirin in patients undergoing coronary artery bypass grafting: A systematic review and meta-analysis. *J. Cardiovasc. Pharmacol. Ther.* 19(1): 97-113.
- Madiyono, B., Sastroasmoro, S., Budiman, I., Purwanto, S.H., 2014. Dasar-dasar metodologi penelitian klinis. Jakarta: Sagung Seto, Indonesia.
- Mahaffey, K.W., Wojdyla, D.M., Carroll, K., Becker, R.C., Storey, R.F., Angiolillo, D.J., Held, C., Cannon, C.P., James, S., Pieper, K.S., Horrow, J., Harrington, R.A., 2011. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) Trial. *Circ. J.* 124: 544-554.
- Makki, N., Brennan, T.M., Girotra, S., 2015. Acute coronary syndrome. *J. Intensive Care Med.* 30: 186-200.
- Marshall, K., 2011. Acute coronary syndrome : Diagnosis, risk assessment and management. *Nurs. Stand.* 25: 47-58.
- Muchid, A., Umar, F., Chusun., 2006. Pharmaceutical care untuk pasien penyakit jantung koroner akut. Indonesia: Jakarta.
- Nakatani, D., Sakata, Y., Suna, S., Usami, M., Matsumoto, S., Shimizu, M., *et al.*, 2013. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. *Circ. J.* 77(2): 439-46.

- Neiger, J., Trohman, R., 2011. Differential diagnosis of tachycardia with a typical left bundle branch block morphology Jeffrey. *World J. Cardiol.* 3: 127-34.
- Niluh, C.E., Rampengan, S.H., Jim, E.L., 2016. Gambaran penyakit jantung koroner pada pasien gagal jantung yang menjalani rawat inap di RSUP Prof . Dr.R.D. Kandou Manado. *eCI. J.* 4: 1- 9.
- Papageorgiou, N., and Tousoulis, D., 2016. Cardiovascular diseases. *TNQ Books and Jour.* 1: 1-2.
- Pejcic, A.V., Jankovis, S.M., Davidovic, G., 2018. Drug–drug interactions in patients with acute coronary syndrome across phases of treatment. *Intern. Emerg. Med. J.* 14(3): 411-422.
- PERKI., 2015. Pedoman tatalaksana sindrom koroner akut. *J. Kardio. Indo.* k3: 1-74.
- Pinto, X., Millian, J., Munoz, A., Corbella, E., Hernandez-Mijares, A., Zuniga, M., Mangas, A., Pedro-Botet, J., 2010. A very high prevalence of low hdl cholesterol in Spanish patients with acute coronary syndromes. *Clin. Cardiol. J.* 33(7): 418-423.
- Rai, M., Goyal, R., 2017. Pharmacoeconomics in healthcare, pharmaceutical medicine and translational clinical research. *Elsevier Inc. J.* 33: 465-471.
- Ramaraj, R., Movahed, M.R., Hashemzadeh, M., 2011. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome. *J. Interv. Cardiol* 24(3): 199-207.
- Rxlist., 2018. <https://www.rxlist.com/plavix-drug.htm#description>, diakses pada tanggal 05 Mei 2018.
- Rxlist., 2018. <https://www.rxlist.com/yosprala-drug.htm#description>, diakses pada tanggal 05 Mei 2018.
- Sagita, V.A., Bahtiar, A., Andrajati, R., 2018. Evaluation of a clinical pharmacist intervention on clinical and drug-related problems among coronary heart disease inpatients. *Sultan Qaboos Univ. Med. J.* 18: 81-87.
- Shi, X-J., Li, M-N., Xuan, L., Li, H., Chen, B., Zhang, J., Wang, H-J., 2019. Clinical characteristics of patients with premature acute coronary syndrome and adverse cardiovascular events after PCI. *Exp. Ther. Med. J.* 18(1): 793-801.

- Singh, S., Singh, M., Grewal, N., and Khosla, S., 2016. Comparative efficacy and safety of prasugrel, ticagrelor, and standard-dose and high-dose clopidogrel in patients undergoing percutaneous coronary intervention. *Am. J. Ther.* 23: 52-62.
- Singh, M., Bhatt, D.L., Stone, G.W., Rihal, C.S., Gersh, B.J., Lennon, R.J., Narula, J., Fuster, V., 2016. Antithrombotic approaches in acute coronary syndromes: optimizing benefit vs bleeding risks. *Mayo Clin. Proc.* 91: 1413-447.
- Singh, S.S., Paul, S.K., Pal, R., Thatkar, P.V., 2017. Acute coronary syndrome-related mortality audit in a teaching hospital at Port Blair, India. *J. Family Med. Prim. Care* 6: 502-508.
- Squizzato, A., Keller, T., Middeldorp, S., 2007. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. *Cochrane Database Syst. Rev.* 12: 1-3.
- Ten Haaf, M.E., Bax, M., Ten Berg, J.M., Brouwer, J., Van't Hof, A.W., van der Schaaf, R.J., Stella, P.R., Tjon Joe Gin, R.M., *et al.*, 2019. Sex differences in characteristics and outcome in acute coronary syndrome patients in the Netherlands. *Neth. Heart J.* 27: 263-271.
- Teng, R., Oliver, S., Hayes, M.A., Butler, K., 2010. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. *Drug Metab. Dispos.* 38: 1514-1521.
- Tofler, G.H., Kopel, E., Klempfner, R., Eldar, M., Buckley, T., Goldenberg, I., 2017. Triggers and timing of acute coronary syndrome. *Am. J. Cardiol.* 119(10): 1560-1565.
- Tourmousoglou, C.E., Rokkas, C.K., 2008. Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence. *Cardio. & Hemato. Agents in Med. Chemistry* 6(4): 312-322.
- Tumade, B., Jim, E.L., Joseph, V.F.F., 2016. Prevalensi sindrom koroner akut di RSUP Prof. Dr. R. D. Kandou Manado periode 1 Januari 2014 – 31 Desember 2014. *J. e-Clinic* 4: 223-230.
- Tuppin, P., Neumann, A., Danchin, N., De Peretti, C., Weill, A., Ricordeau, P., *et al.*, 2010. Evidence-based pharmacotherapy after myocardial infarction in France: Adherence-associated factors and relationship with 30-month mortality and rehospitalization. *Archives of Cardiovascular Diseases* 103(6-7): 363-375.

- Yusuf, S., Zhao, F., Mehtra, S.R, Chrolavicius, S., Tognoni, G., Fox, K.K., 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. *JMC*. 345(7): 494-502.
- Wallentin, L., Becker, R.C., Budaj, A., Cannon, C.P., Emanuelsson, H., Held, C., *et al.*, 2009. Ticagrelor versus clopidogrel in patients with acute coronary syndrome. *N. Engl. J. Med.* 361(11): 1045-1057.
- WHO., 2013. Cardiovascular diseases, Fact sheet N0.317. WHO South-East Asia.
- Wijaya, I.P., Ranitya, R., Ginanjar, E., and Salim, S., 2013. Holistic approaches in cardiovascular diseases symposium xii. Indonesia: Jakarta.